



RNA Horizons 2024 Therapeutics Symposium

Unlocking the RNA's Potential in Medicine

September 25-27, 2024
Alfandega Congress Centre, Porto, Portugal

Dr. Silvia Buonamici grew up in Italy where she completed her graduate training in Molecular Biology and Genetics. During her academia years Silvia studied the pathogenesis of myeloid and lymphoid leukemia in the laboratory of Giuseppina Nucifora and Iannis Aifantis. Silvia in the fall of 2009 joined the oncology department at Novartis Institutes for BioMedical Research where she developed the Hedgehog signaling pathway inhibitor LDE225 (Sonidegib) and the allosteric inhibitor of BCR-ABL, ABL001 (Asciminib) that recently received the FDA approval for locally advanced basal cell carcinoma and Chronic Myeloid Leukemia, respectively. In 2011, she joined H3 Biomedicine, a new cancer genomics based drug discovery company where she began to study the mechanism of action of the spliceosome mutations identified in leukemia and she was responsible for the discovery of the splicing modulator H3B-8800. Afterwards, she helped build several companies at Third Rock Ventures and Atlas Venture before joining Monte Rosa Tx. In 2023 Silvia joined Remix Therapeutics as Senior Vice President of the Translational Research and Bioinformatic department involved in the discovery and development of small molecules used to reprogram RNA processing to address undruggable targets for oncology and beyond. In her spare time, she enjoys spending time with her family, playing with her two kids and exercising.